Compare · GILD vs PRME
GILD vs PRME
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Prime Medicine Inc. (PRME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PRME operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.88B, about 242.3x PRME ($668.0M).
- Over the past year, GILD is up 22.6% and PRME is up 124.2% - PRME leads by 101.5 points.
- GILD has been more active in the news (8 items in the past 4 weeks vs 6 for PRME).
- GILD has more recent analyst coverage (25 ratings vs 15 for PRME).
- Company
- Gilead Sciences Inc.
- Prime Medicine Inc.
- Price
- $130.38-2.48%
- $3.71-3.89%
- Market cap
- $161.88B
- $668.0M
- 1M return
- -5.67%
- +1.64%
- 1Y return
- +22.62%
- +124.17%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2022
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 15
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick
Latest PRME
- SEC Form DEFA14A filed by Prime Medicine Inc.
- SEC Form DEF 14A filed by Prime Medicine Inc.
- SEC Form 4 filed by Makhni Svetlana Ni
- SEC Form 3 filed by new insider Makhni Svetlana Ni
- Prime Medicine Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
- Oppenheimer initiated coverage on Prime Medicine with a new price target
- SEC Form EFFECT filed by Prime Medicine Inc.
- SEC Form S-8 filed by Prime Medicine Inc.
- SEC Form POS AM filed by Prime Medicine Inc.